Publication:
Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Retraction of vol 17, pg 1851, 2016)

dc.contributor.authorSaydam, Güray
dc.contributor.authorHaznedaroğlu, İbrahim C.
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorYavuz, Akif S.
dc.contributor.authorAli, Rıdvan
dc.contributor.authorGüvenç, Birol
dc.contributor.authorAkay, Olga M.
dc.contributor.authorBaşlar, Zafer
dc.contributor.authorÖzbek, Uğur
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorAydın, Demet
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorUndar, Bülent
dc.contributor.authorDağdaş, Simten
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorAkkaynak, Diyar Z.
dc.contributor.authorAkın, Gülnur
dc.contributor.authorİlhan, Osman
dc.contributor.buuauthorALİ, RIDVAN
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDahiliye Kliniği
dc.contributor.researcheridGXD-8209-2022
dc.date.accessioned2024-12-03T11:28:44Z
dc.date.available2024-12-03T11:28:44Z
dc.date.issued2018-10-21
dc.description.abstractObjectives: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL1 <= 0.1% on the International Scale [BCR-ABL1(IS)]) by 12 months.Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300 mg twice daily. This analysis was based on the first 12 months of follow-up in a 24-month study. This study is registered with ClinicalTrials.gov (NCT01274351).Results: Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1(IS) <= 0.0032%) by 12 months. During the first year of treatment, one patient progressed to blast crisis and two patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides.Conclusion: These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP with low and intermediate risk.
dc.description.sponsorshipNovartis
dc.identifier.doi10.1080/10245332.2018.1444919
dc.identifier.eissn1607-8454
dc.identifier.issn1024-5332
dc.identifier.issue9
dc.identifier.urihttps://doi.org/10.1080/10245332.2018.1444919
dc.identifier.urihttps://www.tandfonline.com/doi/abs/10.1080/10245332.2018.1444919
dc.identifier.urihttps://hdl.handle.net/11452/48830
dc.identifier.volume23
dc.identifier.wos000706600000001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherTaylor
dc.relation.journalHematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEarly molecular response
dc.subjectAlpha plus cytarabine
dc.subjectFollow-up
dc.subjectImatinib-resistant
dc.subjectInterferon
dc.subjectInhibitor
dc.subjectAmn107
dc.subjectBcr-abl1
dc.subjectChronic myeloid leukemia
dc.subjectMolecular response
dc.subjectNilotinib
dc.subjectTyrosine kinase inhibitor
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectHematology
dc.subjectHematology
dc.titleOutcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Retraction of vol 17, pg 1851, 2016)
dc.typeRetraction
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dahiliye Kliniği
relation.isAuthorOfPublication578cac50-ce4d-4818-8e99-2634ef340753
relation.isAuthorOfPublication.latestForDiscovery578cac50-ce4d-4818-8e99-2634ef340753

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ali_vd_2018.pdf
Size:
1.61 MB
Format:
Adobe Portable Document Format

Collections